Skip to main content

The human placenta, a target of SARS-CoV-2

Université de Lausanne
What happens in the human placenta after SARS-CoV-2 infection? Research teams led by Dr Marco Alves (Institute of Virology and Immunology IVI, Bern) and Prof David Baud (Lausanne University Hospital, CHUV) found that SARS-CoV-2 can infect the cells of human placenta and that the virus proliferates and infects neighbouring pla-cental cells. The results of their research work have been recently published in the scientific journal Cell Reports Medicine (Fahmi et al, 2021).
© iStock

« This is a major advance in our understanding of COVID-19 during pregnancy », explains Marco Alves, group leader and immunologist at the IVI. « Thousands of infectious viral particles can be produced rapidly in the placenta. In addition, we observed that expression of the SARS-CoV-2 receptor in the placenta is highly variable and specific to each pregnancy, which might explain why the virus sometimes is transmitted to the foetus ».

It is important to remember that pregnant women have a 70% greater risk of becoming infected with SARS-CoV-2 than the general population of the same age. « If they become infected, the risk of a severe progression, i.e. admission to intensive care, is around five to ten percent », explains David Baud, head of obstetrics at the CHUV. The risk of premature delivery is increased by two to three times. It is also known that the risk of foetal death (death in utero) similarly increases by two to three times if the pregnant woman is infected. Pregnant women and their unborn children should therefore be considered as especially vulnerable to SARS-CoV-2.

The study by the Bern and Lausanne research teams strengthens the recommendation of vaccination for pregnant women. To date, several hundred thousand pregnant women have received a messenger RNA vaccine, with no increase in risk to mother and child. Indeed, messenger RNA does not pass into the foetus, while the antibodies developed by the mother cross the placental barrier and will therefore protect the child. “The fact that the virus can infect and proliferate in the placenta demonstrates the need for women to be vaccinated”, say the two researchers. Vaccination against SARS-CoV-2 is currently recommended for all pregnant women in Switzerland.

More information
Institute of Virology and Immunology IVI : communication(at)ivi.admin.ch / +41 58 481 38 88
CHUV : medias(at)chuv.ch /+41 79 556 60 00

About Institute of Virology and Immunology

About Institute of Virology and Immunology
The Institute of Virology and Immunology (IVI) is the federal institute for the diagnosis, monitoring and research of highly infectious and important epizootic diseases of viral origin, including viral zoonoses. As part of a cooperation agreement with the Vetsuisse faculty of the University of Bern, the IVI is also responsible for teaching in the fields of virology and immunology. The IVI reports to the Federal Food Safety and Veterinary Office (FSVO).

Le CHUV en bref

Le CHUV est l’un des cinq centres hospitaliers universitaires suisses, aux côtés des hôpitaux de Genève, Berne, Bâle et Zurich. Il poursuit trois missions de base confiées par les pouvoirs publics: les soins, la formation et la recherche.

En 2023, grâce à ses 12'675 collaborateurs-trices, le CHUV a accueilli 53'964 patient-e-s hospitalisé-e-s. Le CHUV a traité 79'545 urgences en 2023 et accueilli plus 3'154 naissances. Son budget annuel est de près de 1.9 milliard de francs.

Afin d’assurer la formation des médecins, le CHUV est étroitement lié à la Faculté de biologie et de médecine de l’Université de Lausanne. Il collabore également avec les autres institutions universitaires lémaniques (EPFL, ISREC, Institut Ludwig, Université de Genève), les Hôpitaux universitaires de Genève, ainsi qu’avec d’autres hôpitaux, établissements de soins ou institutions, telles la Fédération des hôpitaux vaudois et la Société vaudoise de médecine.

Depuis 2019, le CHUV figure dans le classement des meilleurs hôpitaux du monde, selon le magazine Newsweek.

  • (opens in a new window)